Merck beats third-quarter 2026 estimates, raises adjusted profit outlook

CNBC reports Merck posted adjusted earnings of $2.49 a share and revenue of $18.09 billion for the third quarter of 2026, both above LSEG-survey estimates. The company raised its adjusted earnings outlook but kept the top of its 2026 revenue range unchanged. Keytruda Qlex beat StreetAccount’s sales estimate as Merck works to shift patients to the injection ahead of Keytruda patent expirations beginning in 2028.